We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · December 02, 2019

Efficacy and Safety of Everolimus in Patients With Metastatic RCC After Failure of First-Line Sunitinib or Pazopanib

Urologia Internationalis


Additional Info

Urologia Internationalis
A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients With Metastatic Renal-Cell Carcinoma After Failure of First-Line Sunitinib or Pazopanib (SUNPAZ)
Urol. Int. 2019 Nov 14;[EPub Ahead of Print], M Schostak, P de Geeter, T Decker, A Resch, C Quiering, S Schmitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading